REGIFARM, S.R.L. - søkeresultat

Den europeiske union - ungarsk - EMA (European Medicines Agency)

poteligeo

kyowa kirin holdings b.v. - mogamulizumab - sezary syndrome; mycosis fungoides - daganatellenes szerek - poteligeo kezelésére javallt felnőtt betegek gombás fertőzések előtt súlyos testi sértés (mf), vagy sézary-szindróma (ss), aki kapott már legalább egy előzetes szisztémás kezelés.

Den europeiske union - ungarsk - EMA (European Medicines Agency)

ximluci

stada arzneimittel ag - ranibizumabbal - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - szemészeti - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Den europeiske union - ungarsk - EMA (European Medicines Agency)

pylclari

curium pet france - piflufolastat (18f) - prosztatikus daganatok - diagnosztikai radiofarmakonok - ez a gyógyszer csak diagnosztikai célra használható. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).